This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging ...

DexCom concluded the third quarter of 2024 on a positive note, with earnings and revenues surpassing expectations. Key drivers included significant contributions from the Sensor segment and robust ...

Every study in these AID systems has been done with the DexCom sensor. So there aren't any head-to-head studies. They've all been run with DexCom, at least with our pump partners, and that's the ...

DexCom, Inc. DXCM reported third-quarter 2024 ... The broader S&P 500 index has moved up 21.6% in the same period. Sensor and other revenues (96% of total revenues) increased 9% on a year-over ...

DexCom, Inc. DXCM is scheduled to release third ... Potential robust contributions from the Sensor segment, and domestic and international revenue growth are likely to have been the key catalysts ...

the company reported that it has submitted a 15-day version of its G7 sensor to the FDA for review. Currently, the device can be worn for up to 10 days among users as young as 2 years old. Dexcom ...

While there is some optimism around Dexcom’s efforts to rebuild the Durable Medical Equipment (DME) channel and the filing of the 15-day G-Series sensor with the FDA, the softer US performance ...

Jefferies analyst Matthew Taylor maintained a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The ...

DexCom reports quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents. Quarterly revenue comes in at $994.2 million, which beat the analyst consensus ...